Canaccord Genuity Reiterates a 'Buy' on RTI Biologics (RTIX); Direct Distribution and New Products to Provide Consistency and Growth
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on RTI Biologics (NASDAQ: RTIX), PT $4.75.
Canaccord analyst says, "We reiterate our BUY rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We reiterate our BUY rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
